Assertio Therapeutics Key Fundamental Indicators

Assertio Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 335.7 M 327.4 M 523 M Very volatile Short and Long Term Debt Total 44 M 46.3 M 319.3 M Slightly volatile Total Current Liabilities 74.2 M 131.9 M 117.3 M Pretty Stable Property Plant And Equipment Net 1.9 M 2 M 5.9 M Slightly volatile Accounts Payable 14.7 M 16.9 M 23.3 M Pretty Stable Non Current Assets Total 89.8 M 94.5 M 316.4 M Very volatile Net Receivables 65.3 M 62.2 M 45.7 M Slightly volatile Common Stock Shares Outstanding 7.7 M 7.3 M 5.1 M Very volatile Liabilities And Stockholders Equity 335.7 M 327.4 M 523 M Very volatile Other Current Assets 10 M 11.6 M 15.6 M Very volatile Total Liabilities 240.6 M 188.2 M 371.1 M Very volatile Total Current Assets 136.2 M 232.9 M 200.2 M Pretty Stable Short Term Debt 361.6 K 380.6 K 98.5 M Slightly volatile Cash 79.3 M 58.2 M 117.7 M Slightly volatile Cash And Short Term Investments 96 M 115.1 M 128.6 M Slightly volatile Non Current Liabilities Total 53.5 M 56.3 M 247.2 M Pretty Stable Other Stockholder Equity 959 M 913.3 M 394.6 M Slightly volatile Common Stock 7.7 K 8.1 K 103.6 M Slightly volatile Other Assets 1.09 1.15 24.6 M Very volatile Property Plant Equipment 962.5 K 1 M 5.7 M Slightly volatile Common Stock Total Equity 11.1 K 11.7 K 106 M Slightly volatile Property Plant And Equipment Gross 5.7 M 5.9 M 6.7 M Pretty Stable Other Liabilities 29.7 M 23.8 M 33.9 M Pretty Stable Inventory 46.3 M 44.1 M 16.3 M Slightly volatile Long Term Investments 229.1 K 241.2 K 11.4 M Slightly volatile Non Current Liabilities Other 4.7 M 4.9 M 26.6 M Pretty Stable Capital Surpluse 552.7 M 526.4 M 266.9 M Slightly volatile Deferred Long Term Asset Charges 39.7 M 20.7 M 36.4 M Slightly volatile Long Term Debt Total 402.2 M 244.1 M 349.4 M Very volatile Short and Long Term Debt 401.9 K 423 K 160.3 M Slightly volatile Net Invested Capital 136.6 M 143.8 M 517.1 M Slightly volatile Capital Stock 8.5 K 10.3 K 7.1 K Slightly volatile
Assertio Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Total Revenue 128.4 M 143.7 M 199.6 M Pretty Stable Gross Profit 112.1 M 98.6 M 172.1 M Pretty Stable Other Operating Expenses 145.2 M 171.9 M 218.2 M Pretty Stable Total Operating Expenses 128.9 M 126.7 M 190.7 M Pretty Stable Depreciation And Amortization 26.7 M 29.7 M 42.6 M Pretty Stable Selling General Administrative 99.7 M 86.4 M 104.2 M Pretty Stable Selling And Marketing Expenses 1.5 M 1.6 M 4.9 M Slightly volatile Interest Income 2.8 M 2.9 M 30.1 M Slightly volatile Reconciled Depreciation 45.8 M 23.2 M 74.4 M Slightly volatile
Assertio Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 64.4 M 84.5 M 97.2 M Very volatile Depreciation 26.9 M 29.7 M 43 M Pretty Stable Stock Based Compensation 8.7 M 5.8 M 8.5 M Very volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 0.73 0.76 4.5981 Slightly volatile Days Sales Outstanding 173 182 98.2849 Slightly volatile Average Payables 1.8 M 1.7 M 1.8 M Slightly volatile Stock Based Compensation To Revenue 0.0366 0.0361 0.0457 Very volatile Capex To Depreciation 0.0243 0.0256 0.3372 Slightly volatile EV To Sales 0.64 0.67 4.8707 Slightly volatile Inventory Turnover 0.88 0.92 2.3846 Pretty Stable Days Of Inventory On Hand 323 410 276 Very volatile Sales General And Administrative To Revenue 0.41 0.54 0.5258 Pretty Stable Average Inventory 2.6 M 3.5 M 3.7 M Very volatile Research And Ddevelopement To Revenue 0.0334 0.0352 0.1379 Slightly volatile Capex To Revenue 0.0045 0.0047 0.0232 Slightly volatile Cash Per Share 13.47 14.18 109 Slightly volatile Intangibles To Total Assets 0.41 0.25 0.4511 Pretty Stable Current Ratio 3.34 2.03 2.22 Pretty Stable Receivables Turnover 2.52 2.66 5.1031 Slightly volatile Capex Per Share 0.14 0.15 2.906 Slightly volatile Average Receivables 528.6 K 333.7 K 329.1 K Very volatile Revenue Per Share 16.82 17.71 157 Slightly volatile Interest Debt Per Share 5.83 6.14 218 Pretty Stable Debt To Assets 0.24 0.13 0.3393 Pretty Stable Graham Number 331 214 363 Slightly volatile Operating Cycle 562 592 358 Slightly volatile Long Term Debt To Capitalization 0.34 0.22 0.4412 Pretty Stable Total Debt To Capitalization 0.34 0.22 0.4559 Pretty Stable Quick Ratio 3.23 1.65 2.0848 Pretty Stable Net Income Per E B T 1.24 0.9 1.8187 Pretty Stable Cash Ratio 0.48 0.51 1.901 Slightly volatile Days Of Inventory Outstanding 323 410 276 Very volatile Days Of Sales Outstanding 173 182 98.2849 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 1.11 1.14 0.9994 Pretty Stable Fixed Asset Turnover 69.02 65.73 53.6983 Slightly volatile Debt Ratio 0.24 0.13 0.3393 Pretty Stable Price Sales Ratio 0.73 0.76 4.5981 Slightly volatile Asset Turnover 0.29 0.39 0.4045 Pretty Stable Gross Profit Margin 1.3 0.79 0.9201 Pretty Stable
Assertio Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 80.5 M 84.7 M 354.2 M Slightly volatile Enterprise Value 113.9 M 119.8 M 553.5 M Slightly volatile

Assertio Fundamental Market Drivers

Assertio Upcoming Events

Assertio Current Valuation Driver Correlations

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details

Assertio Therapeutics 'What if' Analysis

Hype Prediction Low Estimated High 8.92 12.35 15.78 Details

Intrinsic Valuation Low Real High 11.14 17.99 21.42 Details

4 Analysts Consensus Low Target High 34.07 37.44 41.56 Details

Earnings Estimates (0) Low Projected EPS High -0.75 -0.75 -0.75 Details

Assertio Therapeutics February 15, 2026 Technical Indicators

Assertio Therapeutics Backtested Returns

Competition

Predict Assertio Therapeutics

Enterprise Value Over Time

Assertio Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Assertio Therapeutics's current stock value. Our valuation model uses many indicators to compare Assertio Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Assertio Therapeutics competition to find correlations between indicators driving Assertio Therapeutics's intrinsic value. More Info.Assertio Therapeutics is rated third in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Assertio Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Assertio Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Assertio Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assertio Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assertio Therapeutics could also be used in its relative valuation, which is a method of valuing Assertio Therapeutics by comparing valuation metrics of similar companies.

Assertio Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Assertio Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Assertio Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Assertio Fundamentals

About Assertio Therapeutics Fundamental Analysis

Please read more on our fundamental analysis page.

Additional Tools for Assertio Stock Analysis